Peptides that are involved in sexual function operate differently
The GLP-1 Effect: Market Penetration In the UK, 4.2 million adultsnearly 1 in 10had recently used a GLP-1 medication or expressed interest in doing so as of early 2025 Two in five overweight Britons (38%) express interest in using GLP-1s for weight loss when informed about the drugs Across Europe, the GLP-1 market is valued at 9.62 billion in 2025, with robust growth expected due to rising obesity and diabetes rates, improved access, and strong healthcare infrastructure in markets like Germany, France, and the UK Social acceptance is rising, and insurance coverage is likely to expand, further accelerating adoption
In addition to increasing insulin, semaglutide slows down how fast the stomach empties food
This finding was likewise reported by Oelsner et al
Maintain realistic expectations and understand that skin responds gradually
In addition, semaglutide works in a glucose-dependent way